Low Serum Levels of HtrA3 at 15 Weeks of Gestation Are Associated with Late-Onset Preeclampsia Development and Small for Gestational Age Birth

Sonia Soo Yee Teoh, Yao Wang, Ying Li, Shalem Yiner Lee Leemaqz, Gus A. Dekker, Claire T. Roberts, Guiying Nie

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


Objective: The aim of this study was to investigate the potential utility of serum HtrA1 and HtrA3, serine proteases that are highly expressed in the developing placenta, at 15 and 20 weeks of gestation for predicting later development of adverse pregnancy outcomes of preeclampsia (PE), gestational hypertension (GHT), preterm birth (PTB), and small for gestational age (SGA) birth. Methods: This is a nested case control study of 665 samples (330 controls, 335 cases) from the Adelaide SCOPE cohort. The cases included were 92 PE, 71 GHT, 56 PTB, and 116 SGA. Samples were assessed by ELISA and data adjusted for maternal age, BMI, socioeconomic index, hCG, and smoking status. Multivariate logistic regression was performed with other biochemical and biophysical parameters available for these samples. Results: HtrA1 did not differ between the controls and cases. In contrast, HtrA3 was significantly lower at 15 weeks in pregnancies that later developed late-onset PE (LPE) or resulted in SGA birth, with an area under the ROC curve (AUC) of 0.716 and 0.790, respectively. The combination of HtrA3 with PAPP-A, uterine, and umbilical Doppler improved the AUC to 0.755 for LPE and 0.844 for SGA. Conclusion: HtrA3 at 15 weeks is associated with, and may be useful for, the early detection of LPE development and SGA birth.

Original languageEnglish
Number of pages10
JournalFetal Diagnosis and Therapy
Publication statusAccepted/In press - 3 Apr 2019


  • Biomarkers
  • HtrA1
  • HtrA3
  • Late-onset preeclampsia
  • Preeclampsia
  • Small for gestational age

Cite this